Physician profile
Anthony E Marl
NPI 1689694671
$1,409.67
in general payments reported to CMS, 2019-2025
22 companies · $51.55 in 2025
The $51.55 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $380 · 2021: $200 · 2022: $157 · 2023: $102 · 2024: $151 · 2025: $51.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.58 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $188.85 | 2021-2024 | |
| Pfizer INC. | $161.78 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $98.88 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Glaxosmithkline, LLC. | $74.21 | 2019-2022 | |
| Lilly USA, LLC | $70.73 | 2020-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $60.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $47.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.50 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $35.08 | 2019 | |
| Astellas Pharma US INC | $29.45 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.61 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.52 | 2024 | Stiolto Respimat, Spiriva Respimat |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.78 | 2019 | |
| Amarin Pharma, INC. | $21.92 | 2021 | |
| Exact Sciences Corporation | $16.23 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $16.12 | 2021 | |
| Boston Scientific Corporation | $13.43 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.